Form 8-K - Current report:
SEC Accession No. 0001213900-25-053292
Filing Date
2025-06-11
Accepted
2025-06-11 09:20:57
Documents
15
Period of Report
2025-06-11
Items
Item 5.03: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year
Item 8.01: Other Events
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 CURRENT REPORT ea0245328-8k_cero.htm   iXBRL 8-K 56155
2 CERTIFICATE OF AMENDMENT TO THE SECOND AMENDED AND RESTATED CERTIFICATE OF INCOR ea024532801ex3-1_cero.htm EX-3.1 16463
3 PRESS RELEASE, DATED JUNE 11, 2025 ea024532801ex99-1_cero.htm EX-99.1 16616
  Complete submission text file 0001213900-25-053292.txt   314988

Data Files

Seq Description Document Type Size
4 XBRL SCHEMA FILE cero-20250611.xsd EX-101.SCH 3797
5 XBRL DEFINITION FILE cero-20250611_def.xml EX-101.DEF 26672
6 XBRL LABEL FILE cero-20250611_lab.xml EX-101.LAB 36816
7 XBRL PRESENTATION FILE cero-20250611_pre.xml EX-101.PRE 25296
17 EXTRACTED XBRL INSTANCE DOCUMENT ea0245328-8k_cero_htm.xml XML 6059
Mailing Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080
Business Address 201 HASKINS WAY SUITE 230 SOUTH SAN FRANCISCO CA 94080 650-407-2376
CERO THERAPEUTICS HOLDINGS, INC. (Filer) CIK: 0001870404 (see all company filings)

EIN.: 871088814 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-40877 | Film No.: 251038902
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)